Testosterone Enanthate Side Effects: Which Ones Can Become Permanent?

What Makes a Testosterone Enanthate Side Effect "Potentially Permanent"?

Most testosterone enanthate adverse effects are dose-dependent and reverse within weeks to months of stopping the drug. A subset, however, involves structural changes, prolonged axis suppression, or tissue remodeling that persists well beyond the drug's pharmacokinetic clearance.

Testosterone enanthate has a half-life of approximately 4.5 days, so it clears plasma in roughly three weeks. The downstream effects on the hypothalamic-pituitary-gonadal (HPG) axis, red-cell mass, and cardiac muscle can outlast drug clearance by months or years. The FDA-approved prescribing label for testosterone enanthate injection explicitly warns of polycythemia, peliosis hepatis, and potential for virilization in women, with the label noting these effects "may be irreversible even after prompt discontinuance." [1]

Understanding which effects are slow-to-reverse versus truly irreversible shapes the monitoring protocol and the informed consent conversation every prescriber must have before initiating therapy.

Testicular Atrophy and HPG Axis Suppression

Exogenous testosterone suppresses the HPG axis rapidly. This is the mechanism most users encounter first, and it is the source of the most prolonged post-treatment recovery challenges.

Why Suppression Occurs

Supraphysiologic or even physiologic exogenous androgen signals the hypothalamus to reduce gonadotropin-releasing hormone (GnRH) pulsatility. Luteinizing hormone (LH) and follicle-stimulating hormone (FSH) fall, often to undetectable levels within two weeks of initiating TE. Without LH stimulation, Leydig cells stop producing endogenous testosterone. Without FSH, Sertoli cells reduce spermatogenesis. The testes lose volume at a rate proportional to dose and duration. [2]

How Long Does Recovery Take?

A 2013 systematic review published in the Journal of Clinical Endocrinology and Metabolism found that among men who used androgenic anabolic steroids, 90% recovered spermatogenesis within 24 months of cessation, but recovery was significantly slower for men who used for longer than 12 months and those who used higher cumulative doses. [3] The remaining 10% showed no recovery at 24 months, suggesting a fraction of users sustain permanent hypogonadism.

Recovery of endogenous testosterone production typically lags behind sperm recovery. Serum testosterone may remain below 300 ng/dL for 6 to 12 months after stopping TE, even in men who eventually recover fully. Clinicians sometimes prescribe human chorionic gonadotropin (hCG) or selective estrogen receptor modulators (SERMs) like clomiphene 25 to 50 mg daily to shorten this window, though neither is FDA-approved specifically for this indication. [4]

When Suppression Becomes Permanent

Men who use high-dose TE (above 400 mg/week) for more than 24 consecutive months may develop permanent secondary hypogonadism. Leydig cell number can decline with prolonged suppression, and testicular volume loss greater than 30% correlates with longer recovery times and poorer prognosis for spontaneous testosterone normalization. [3]

Male Infertility and Azoospermia

Scope of the Problem

Testosterone enanthate is, in pharmacologic terms, a highly effective male contraceptive. The WHO 1990 contraceptive study (N=271) demonstrated that 98% of men reached severe oligospermia (<1 million/mL) on 200 mg TE weekly, with 65% reaching full azoospermia. Contraceptive failure rates were low while suppression was maintained. [5] These numbers also define the fertility risk for men using TE for other purposes.

Reversibility Window

For the majority of men, sperm counts recover after stopping TE. Recovery is faster when duration of use is under 12 months. However, recovery is not universal, and waiting more than 24 months without recovery substantially reduces the probability of spontaneous return of fertility. Men who want to preserve fertility should bank sperm before starting TE, a recommendation echoed by the American Urological Association and the Endocrine Society 2018 clinical practice guideline on testosterone therapy. [6]

What Speeds Recovery

Post-cycle protocols using FSH injections (75 IU three times weekly) combined with hCG (500 to 1,500 IU three times weekly) have shown faster spermatogenic recovery compared to watchful waiting in small prospective series. These protocols are off-label but widely used in fertility medicine. [4]

Erythrocytosis and Polycythemia Vera Risk

The Mechanism

Testosterone directly stimulates erythropoiesis in bone marrow and suppresses hepcidin, raising serum iron availability for red cell production. Hematocrit routinely rises on TE. The FDA label requires monitoring hematocrit before initiating therapy and periodically during treatment, with a warning that polycythemia has occurred with androgens. [1]

Clinical Thresholds

Most guidelines use hematocrit >54% as the threshold for dose reduction or therapeutic phlebotomy. The Endocrine Society 2018 guideline states: "We recommend checking a hematocrit before starting testosterone therapy and rechecking it at 3 to 6 months and then annually; if hematocrit exceeds 54%, we recommend withholding testosterone therapy." [6]

Hematocrit typically returns to baseline within three to six months after stopping TE. The concern for permanence arises in two scenarios. First, men with undiagnosed JAK2-mutation-positive polycythemia vera may have their underlying condition unmasked by TE. Second, chronic erythrocytosis raises thrombotic risk (deep vein thrombosis, pulmonary embolism, stroke) that can cause permanent end-organ damage, even after hematocrit normalizes. A FAERS analysis through 2022 identified thromboembolic events as one of the most reported serious adverse events associated with testosterone products. [7]

Monitoring Protocol

Check a complete blood count at baseline, at 3 months, and then annually. Therapeutic phlebotomy (removal of 450 to 500 mL whole blood) rapidly reduces hematocrit and is often used as a bridge while dose adjustments take effect.

Cardiovascular Remodeling and Arrhythmia

Cardiovascular adverse effects of testosterone therapy have been debated for over a decade. The TRAVERSE trial provided the largest randomized dataset to date.

TRAVERSE Trial Findings

TRAVERSE (N=5,246, median 33 months follow-up) was a non-inferiority trial comparing testosterone gel versus placebo in men with hypogonadism and elevated cardiovascular risk. Published in the New England Journal of Medicine in 2023, TRAVERSE showed non-inferiority for major adverse cardiovascular events (MACE). However, the testosterone arm showed a statistically significant higher rate of atrial fibrillation (3.5% vs. 2.4%, P<0.001), pulmonary embolism (0.9% vs. 0.5%), and acute kidney injury. [8]

Testosterone enanthate (injectable) tends to produce higher peak androgen levels than transdermal preparations studied in TRAVERSE. Whether the arrhythmia signal applies equivalently to TE is unknown, but mechanistic data support the concern. Supraphysiologic testosterone promotes left ventricular hypertrophy (LVH), a structural change that may persist for years after cessation and independently raises arrhythmia and sudden cardiac death risk. [9]

Left Ventricular Hypertrophy

A 2017 meta-analysis in the Journal of the American Heart Association found that anabolic-androgenic steroid users had measurably greater left ventricular wall thickness and reduced diastolic function compared to non-users, with effects that persisted in former users studied 12 months post-cessation. [9] LVH regression after stopping TE may take one to three years and is incomplete in some individuals.

Lipid Panel Changes

TE reliably reduces HDL cholesterol. In the Testosterone Trials (TTrials, N=790), testosterone use reduced HDL by approximately 4 to 5 mg/dL at 12 months. [10] LDL may rise modestly. These changes return to baseline within three to six months of stopping, but cumulative atherogenic exposure during treatment adds to lifetime cardiovascular risk in a way that does not fully reverse.

Gynecomastia: When Breast Tissue Becomes Permanent

Mechanism

Testosterone converts to estradiol via aromatization. Rising estradiol stimulates ductal and glandular breast tissue proliferation in men. Gynecomastia affects an estimated 10 to 25% of men on testosterone therapy, with rates higher at larger doses and in men with higher baseline aromatase activity or body fat percentage. [11]

The Reversibility Threshold

Early gynecomastia (puffy nipples, tenderness) that develops in the first four to six months of TE use may regress when estradiol is brought into range using an aromatase inhibitor (anastrozole 0.5 to 1 mg twice weekly is common off-label) or when TE is discontinued. Glandular tissue that has been present for more than 12 months typically becomes fibrotic and does not regress with pharmacologic intervention. Surgical excision (subcutaneous mastectomy) is the only definitive treatment for established gynecomastia. [11]

Early monitoring of estradiol (target 20 to 40 pg/mL on most laboratory references) and prompt aromatase inhibitor use if estradiol rises above 60 pg/mL may prevent progression to irreversible glandular fibrosis.

Virilization in Women: Largely Irreversible Effects

Women prescribed TE (typically at lower doses for hypoactive sexual desire disorder or gender-affirming hormone therapy) face virilizing effects, several of which are irreversible.

Reversible Effects

• Acne
• Oily skin
• Increased body and facial hair (partially reversible; hair follicles may persist)
• Clitoral sensitivity changes (early stage)

Potentially Irreversible Effects

The FDA label for testosterone enanthate states explicitly that virilization in women "may not be reversible." Specifically:

• Clitoral enlargement. Clitoral tissue responds to androgens structurally. Enlargement beyond mild degrees does not regress after drug discontinuation. [1]
• Voice deepening. Laryngeal cartilage growth and vocal cord thickening caused by sustained androgen exposure are permanent. Voice changes documented after six or more months of supraphysiologic TE in women are generally not reversible. [12]
• Facial hair patterns. Terminal hair conversion (vellus to terminal follicles) on the chin, upper lip, and sideburns is largely irreversible; laser hair removal or electrolysis can treat the result but the follicular change persists.

Women receiving TE should have serum testosterone measured at baseline and at four to six weeks after any dose change, with the goal of keeping levels within the physiologic female range (20 to 70 ng/dL) to minimize virilization risk.

Hepatotoxicity: Peliosis Hepatis and Liver Adenoma

Injectable testosterone esters, including TE, carry lower hepatotoxicity risk than 17-alpha-alkylated oral androgens. However, the FDA label warns of peliosis hepatis (blood-filled cysts in liver parenchyma) with androgen use. Peliosis is rare but potentially life-threatening. It has been reported in patients on long-duration androgen therapy and may not fully resolve after drug withdrawal. [1]

Liver adenomas associated with androgens may persist or require surgical resection even after stopping TE. Routine liver function tests are not sensitive for peliosis, which is better detected on MRI in symptomatic patients.

Sleep Apnea Exacerbation

Testosterone therapy worsens obstructive sleep apnea (OSA) in predisposed individuals by altering central respiratory drive and upper airway muscle tone. The FDA label includes OSA as a risk factor requiring monitoring. [1] Pre-existing OSA can progress to a severity that requires CPAP dependency even after TE is stopped, because the structural changes in pharyngeal tissue and weight gain that co-occur with androgen use may persist.

Prostate Effects

TE raises prostate-specific antigen (PSA) modestly (typically by 0.3 to 0.5 ng/mL) within the first year. The Endocrine Society 2018 guideline recommends baseline PSA before initiating therapy and repeat PSA at 3 to 6 months. [6] There is no definitive evidence that physiologic testosterone replacement initiates prostate cancer in men with previously normal prostate tissue. However, TE is absolutely contraindicated in men with known or suspected prostate cancer, because it may accelerate growth of androgen-sensitive tumor cells. This stimulatory effect on an existing occult cancer could produce permanent harm even after TE is stopped.

Injection Site Complications

Repeated intramuscular injections of TE into the same site can cause local fibrosis, lipohypertrophy, and in rare cases sterile abscess formation. Fibrotic changes at injection sites may be permanent. Rotating between gluteal quadrants and alternating sides reduces this risk. Oil microembolism to the pulmonary vasculature is a rare but serious reported adverse event with IM oil-based injections, documented in case literature published in JAMA. [13]

Original Decision Framework for Monitoring and Risk Mitigation

The table below organizes TE adverse effects by reversibility category and recommended monitoring action. This framework was developed by the HealthRX clinical team for use in pre-treatment counseling.

| Adverse Effect | Reversibility | Key Monitoring | Mitigation | |---|---|---|---| | HPG axis suppression | Usually reversible; 10% may be permanent | LH, FSH, total testosterone at 3 months post-stop | hCG + SERM post-cycle if fertility needed | | Azoospermia | Usually reversible <12 months use; uncertain >24 months | Semen analysis 6 months post-stop | Sperm banking pre-treatment | | Erythrocytosis | Reversible within 3 to 6 months | CBC at baseline, 3 months, annually | Phlebotomy if hematocrit >54% | | LVH/cardiac remodeling | Partially reversible over 1 to 3 years | Echocardiogram if >12 months high-dose use | Limit dose and duration | | Atrial fibrillation | Depends on structural remodeling extent | ECG if symptomatic palpitations | Rate control; TE dose reduction | | Gynecomastia | Early: reversible. Late (>12 months): surgical only | Estradiol every 3 to 6 months | Anastrozole; early estradiol management | | Virilization (women) | Clitoral enlargement and voice deepening: largely permanent | Serum testosterone monthly until stable | Keep testosterone in female range | | Peliosis hepatis | May be permanent | MRI if right upper quadrant pain | Stop TE; surgical if needed | | Prostate cancer stimulation | Permanent if advanced | PSA at baseline, 3 to 6 months | Contraindicated with prostate cancer |

Who Is at Highest Risk for Permanent Effects?

Not every TE user faces the same risk profile. Certain patient characteristics substantially raise the probability of encountering a permanent or slow-to-reverse adverse event.

Men over age 40 who use doses above 200 mg per week for more than 12 consecutive months, who have pre-existing cardiovascular disease, sleep apnea, or a family history of polycythemia vera, carry the highest risk. Women who use doses that produce supraphysiologic serum testosterone levels (above 70 ng/dL in a female physiologic context) for more than six months face the highest virilization risk.

The Endocrine Society guideline notes: "We recommend against initiating testosterone therapy in patients who desire fertility in the near term." [6] This recommendation reflects the prolonged and uncertain recovery trajectory for spermatogenesis after androgen exposure.

Young men who use TE for athletic performance enhancement (doses often 300 to 600 mg/week or higher, far above the standard 50 to 200 mg/week therapeutic range) face compounded risk for all the above categories, plus greater cumulative exposure to supraphysiologic estradiol and greater testicular atrophy severity.

What Happens If You Stop Testosterone Enanthate Abruptly?

Stopping TE abruptly rather than tapering does not worsen long-term recovery for most adverse effects and may speed up some. The exception is cardiovascular stability. Abrupt cessation can unmask adrenergic symptoms, mood instability, and fatigue from acute hypogonadism while the HPG axis is still suppressed. These symptoms are transient but can be severe enough to trigger resumption of TE, perpetuating the cycle.

A supervised cessation plan, monitoring serum testosterone, LH, FSH, and estradiol at six-week intervals, allows the clinician to intervene with temporary hCG or SERM support if the HPG axis fails to restart within three months. Men who show no LH or FSH rise at three months post-cessation should be evaluated for secondary hypogonadism, which may require long-term testosterone replacement regardless of the original indication for TE. [6]